151 related articles for article (PubMed ID: 32827545)
1. Preparation of RGD4C fused anti-TNFα nanobody and inhibitory activity on triple-negative breast cancer in vivo.
Ji X; Han T; Kang N; Huang S; Liu Y
Life Sci; 2020 Nov; 260():118274. PubMed ID: 32827545
[TBL] [Abstract][Full Text] [Related]
2. Neutralization of TNFα in tumor with a novel nanobody potentiates paclitaxel-therapy and inhibits metastasis in breast cancer.
Ji X; Peng Z; Li X; Yan Z; Yang Y; Qiao Z; Liu Y
Cancer Lett; 2017 Feb; 386():24-34. PubMed ID: 27832973
[TBL] [Abstract][Full Text] [Related]
3. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
4. Dual-targeting liposomes with active recognition of GLUT
Pu Y; Zhang H; Peng Y; Fu Q; Yue Q; Zhao Y; Guo L; Wu Y
Eur J Med Chem; 2019 Dec; 183():111720. PubMed ID: 31553933
[TBL] [Abstract][Full Text] [Related]
5. 14, 15-EET induces breast cancer cell EMT and cisplatin resistance by up-regulating integrin αvβ3 and activating FAK/PI3K/AKT signaling.
Luo J; Yao JF; Deng XF; Zheng XD; Jia M; Wang YQ; Huang Y; Zhu JH
J Exp Clin Cancer Res; 2018 Feb; 37(1):23. PubMed ID: 29426357
[TBL] [Abstract][Full Text] [Related]
6. Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.
Liubomirski Y; Lerrer S; Meshel T; Morein D; Rubinstein-Achiasaf L; Sprinzak D; Wiemann S; Körner C; Ehrlich M; Ben-Baruch A
Front Immunol; 2019; 10():804. PubMed ID: 31105691
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases.
Shin SU; Cho HM; Das R; Gil-Henn H; Ramakrishnan S; Al Bayati A; Carroll SF; Zhang Y; Sankar AP; Elledge C; Pimentel A; Blonska M; Rosenblatt JD
Cells; 2021 Oct; 10(11):. PubMed ID: 34831127
[TBL] [Abstract][Full Text] [Related]
8. Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.
Parvani JG; Gujrati MD; Mack MA; Schiemann WP; Lu ZR
Cancer Res; 2015 Jun; 75(11):2316-2325. PubMed ID: 25858145
[TBL] [Abstract][Full Text] [Related]
9. α
Zhong P; Gu X; Cheng R; Deng C; Meng F; Zhong Z
Int J Nanomedicine; 2017; 12():7913-7921. PubMed ID: 29138558
[TBL] [Abstract][Full Text] [Related]
10. The anticancer properties and mechanism of action of tablysin-15, the RGD-containing disintegrin, in breast cancer cells.
Deng Z; Chai J; Zeng Q; Zhang B; Ye T; Chen X; Xu X
Int J Biol Macromol; 2019 May; 129():1155-1167. PubMed ID: 30660566
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
Jin K; Pandey NB; Popel AS
Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755
[TBL] [Abstract][Full Text] [Related]
12. Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.
Liu J; Chen X; Ward T; Pegram M; Shen K
Tumour Biol; 2016 Jul; 37(7):9825-35. PubMed ID: 26810188
[TBL] [Abstract][Full Text] [Related]
13. Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers.
Camorani S; Crescenzi E; Gramanzini M; Fedele M; Zannetti A; Cerchia L
Sci Rep; 2017 Apr; 7():46659. PubMed ID: 28425453
[TBL] [Abstract][Full Text] [Related]
14. Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis.
Yang HL; Thiyagarajan V; Shen PC; Mathew DC; Lin KY; Liao JW; Hseu YC
J Exp Clin Cancer Res; 2019 May; 38(1):186. PubMed ID: 31068208
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
[TBL] [Abstract][Full Text] [Related]
16. A novel cystathionine γ-lyase inhibitor, I194496, inhibits the growth and metastasis of human TNBC via downregulating multiple signaling pathways.
Liu Y; Wang L; Zhang X; Deng Y; Pan L; Li H; Shi X; Wang T
Sci Rep; 2021 Apr; 11(1):8963. PubMed ID: 33903672
[TBL] [Abstract][Full Text] [Related]
17. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.
Wu C; Qiu S; Liu P; Ge Y; Gao X
J Ethnopharmacol; 2018 Jan; 211():89-100. PubMed ID: 28962890
[TBL] [Abstract][Full Text] [Related]
18. Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals.
Liang S; Chen Z; Jiang G; Zhou Y; Liu Q; Su Q; Wei W; Du J; Wang H
Cancer Lett; 2017 Feb; 386():12-23. PubMed ID: 27836733
[TBL] [Abstract][Full Text] [Related]
19. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
20. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
